07:39 AM EST, 02/06/2025 (MT Newswires) -- Immunovant ( IMVT ) reported a fiscal Q3 loss Thursday of $0.76 per diluted share, wider than a loss of $0.36 a year earlier.
Four analysts polled by FactSet expected a loss of $0.73.
As of Dec. 31, 2024, the company said it had cash and cash equivalents of $374.7 million.